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A growing number of drugs exhibit selective toxicity for the
kidney, the clinical expression of which may range from a mild
disturbance of a discrete function to a generalized depression of
all functions. The magnitude of the problem has stimulated
research into the mechanisms underlying the susceptibility of
the kidney to drug-induced alterations of function and struc-
ture. From such studies has emerged new insights into the
metabolic interactions between specific drugs and renal tubulo-
interstitial cells that underlie the development of toxic injury.
This paper will review current concepts of the selective suscep-
tibility of the renal tubulointerstitium to drug-induced toxicity.
Space does not permit a comprehensive treatment of this
complex subject; therefore a limited number of drugs or other
xenobiotics to serve as examples of generic mechanisms have
been selected for discussion.
Determinants of drug cytotoxicity
The toxic as well as the therapeutic activity of a drug is
critically dependent on the concentration of the active moiety
reaching sensitive target sites. In the case of the kidney,
exposure to increased concentration of a drug or its metabolite
typically derives from the fact that the kidney is the major route
by which the offending agent is eliminated from the body.
Depending on the specific mechanisms mediating drug elimina-
tion by the kidney, different portions of the nephron may be
exposed to the drug or its metabolite. For example, the renal
excretion of certain drugs is accomplished by tubular secretion
via the organic anion transport system of proximal tubular cells.
Consequently these cells may be exposed to high intracellular
concentrations of potentially toxic agents. In other instances
active tubular absorption may generate toxic concentrations of
the offending agent. Any time the fractional absorption of water
exceeds the fractional absorption of drug the lumenal concen-
tration of drug will rise. This pattern is commonly seen with
polar drugs or their derivatives, and during antidiuresis high
concentrations of these compounds may be generated in distal
tubular fluid, so that despite low permeability of the lumenal
membrane, collecting duct cells may be exposed to toxic
intracellular concentrations of drug.
In other instances the susceptibility of the kidney to the toxic
effect of a drug derives from the fact that during the process of
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renal excretion the drug undergoes bioactivation to a reactive
metabolite El]. Xenobiotics are metabolized by a wide variety of
enzymes and these have been classified under two broad
categories [2, 31. Phase I reactions include oxidations, reduc-
tions and hydrolyses, the products of which may be highly
reactive and potentially toxic because of their ability to induce
oxidative stress and/or to bind to macromolecules. Phase I
reactions are commonly coupled to phase II reactions, which in
general are conjugation or synthetic mechanisms such as gluc-
uronidation, sulfation, acylation, methylation and glutathion-
ation. Phase II reactions usually generate highly polar, water
soluble, and biologically inactive products which can be readily
excreted in the urine. However, in some cases phase II reaction
products prove to be toxic. The optimal arrangement for
protecting the cell against injury from phase I reactions is to
have the metabolic machinery for phase I and phase II reactions
in the same cell. As will become apparent this arrangement does
not exist for all regions of the kidney. Moreover, even when
present these pathways may become saturated or critical com-
ponents may be depleted so that toxic intermediates may
accumulate.
The largest capacity for the metabolic transformation of
drugs resides in the liver. The same enzymatic pathways
present in the liver are also found in the kidney, although the
specific activity of these pathways in the kidney are, as a
general rule, substantially lower than those in the liver [2, 31. Of
toxicological significance these metabolic pathways are not
uniformly distributed throughout the kidney; rather they are
localized to specific nephron segments or regions of the kidney
(Table 1). This heterogenous metabolic profile of the kidney
explains the susceptibility of certain areas of the kidney to
injury from crtain xenobiotics.
Figure 1 summarizes the major pathways by which a drug
(X), a stable metabolite (Mr) or a reactive metabolite (Mi) may
interact adversely with a cell. In general the toxic effect of a
drug on an intracellular target is determined by the concentra-
tionz of the toxicant at the target site, and the duration of
exposure of the target to the offending drug or metabolite.
Major determinants for pathways 1 and 2 (Fig. 1) include: the
quantity of drug ingested; the rate of drug metabolism at an
extrarenal site, typically the liver; the rate at which drug or
metabolite is delivered to the kidney; and the rate at which drug
or metabolite is transported into and out of the cell. The activity
of pathway 6(Fig. I), in addition to thefactors just mentioned,
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Table 1. Intrarenal distribution of enzymes that participate in the
biotransformation of xenobiotics
RC or PT OM IM Reference
Cytochrome P-450 MFO 4+ 2+ tr [34—36]
NADPH cytochrome 4+ 2+ 2+ [34, 36]
reductase
UDP-glucuronosyl transferase 4+ 2+ — [95]
Sulfotransferase 4+ 2+ — [95]
GSSG reductase 4+ 2+ 2+ [80]
)GT 4+ 2+ tr [80, 84, 86]
GPx-I 4+ 2+ tr [80]
GPx-lI 4+ 2+ 1+ [80]
PGES tr 2+ 4+ [70, 72—741
The highest activity for a specific enzyme among the three regions of
the kidney was designated 4+ irrespective of the absolute activity.
Abbreviations are: RC, renal cortex; PT, proximal tubule; OM, outer
medulla; IM, inner medulla; yGT, y-glutamyltranspeptidase; GPx-l,
glutathione peroxidase-I; GPx-II, glutathione peroxidase-Il; PGES,
prostaglandin endoperoxide synthetase; tr, trace.
will be determined by the rate at which the reactive metabolite
(Mi) is generated (pathways 3 and 4) and the rate at which the
reactive metabolite is inactivated (pathway 5). The activity of
each pathway may be influenced by genetic factors, by drugs
which induce or inhibit the pathway, and by the availability of
co-factors required for optimal function of the pathway. In
subsequent sections representative examples of these different
pathways will be discussed.
Role of active transport
Aminoglycoside antibiotics (AGs)
AGs exhibit the capacity to disrupt the metabolism, function
and structure of renal proximal tubular cells [4, 5]. In humans
even therapeutic doses of these drugs commonly cause proxi-
mal tubular cell necrosis. The toxicity of AGs is determined by
the interaction of two processes: the extent to which these
drugs are accumulated by proximal tubular cells and the poten-
tial of these drugs to react with intracellular targets [4, 6]. AGs
are excreted unchanged almost exclusively via the kidneys, and
the dominant mechanism of renal excretion is glomerular filtra-
tion [7]. Of relevance to the toxicology of AGs is the fact that a
small fraction of filtered drug is transported by a low affinity but
high capacity system into proximal tubular cells, and due to the
slow rate at which drug is released from these cells, toxic
intracellular concentrations of drug can be attained even during
standard therapy [7]. The transport of AGs across the apical
membrane of proximal tubular cells is mediated, at least in part,
by adsorptive endocytosis, followingwhich the drug is translo-
cated to the lysosomal compartment where it may reach m
concentrations [7]. Indirect evidence also implicates a small
component of uptake across the basolateral membrane by an as
yet undefined mechanism [7].
The relevance of cellular transport and accumulation of drug
to the pathogenesis of toxicity is supported by the following: 1)
necrosis is confined to cells of the nephron segment where the
drug is absorbed [4, 61; 2) for a given antibiotic the risk of
toxicity increases as the renal cortical concentration of drug
increases [4, 6, 71; 3) rats with diabetes mellitus are resistant to
aminoglycoside nephrotoxicity due to the fact that these rats
accumulate less drug in the renal cortex than do sensitive
non-diabetic rats [8, 9]; and 4) this resistance can be overcome
by augmenting the renal cortical concentration of drug [9].
However, the ranking of individual AGs according to the extent
to which they are transported and accumulated by renal prox-
imal tubular cells does not predict the clinical nephrotoxicity
potentials of these drugs because this classification method fails
to take into consideration the second major determinant AG
toxicity, that is, the potential of these drugs to interact with and
disrupt one or more critical intracellular targets.
Insight into the fundamental mechanism underlying AG tox-
icity has been gleaned from studies of the interaction of these
drugs with phospholipids. It has been established that AGs,
which are organic polycations and carry a net cationic charge
ranging from +3.10 for tobramycin to +4.37 for neomycin [10],
preferentially bind to anionic phospholipids, especially phos-
phatidylinositol-4-5'-bisphosphate (PIP2), whereas little or no
binding to anionic non-lipid compounds is observed [11, 12].
This has lead to the hypothesis that anionic phospholipids
function as membrane receptors for these drugs [5, 7, 11]. It
also has been established that AGs induce a phosphatidylinosi-
tol (P1)-enriched phospholipidosis in the renal cortex and in
cells grown in culture [5, 13] due primarily to impaired degra-
dation of phospholipid at the level of the lysosome, the subcel-
lular site where AGs accumulate in high concentration in
association with phospholipid in the form of myeloid bodies, the
typical ultrastructural lesion of AG toxicity. The impaired
degradation of phospholipids is due to AG-induced inhibition of
lysosomal phospholipases, presumably consequent to drug-
substrate complexation [14]. Binding of the cationic AGs to
anionic PIP2 is probably responsible for the disruption of the P1
cascade by these agents [15].
These perturbations of phospholipid metabolism have stimu-
lated investigations into the molecular mechanisms by which
AGs bind to anionic phospholipids of model membranes and the
effects of such binding on the biophysical properties of the
membranes [11, 16—18]. We recently reported that binding of
AGs to anionic phospholipid is mediated by an electrostatic
interaction between the positively-charged amino groups of the
drug and the negatively charged phosphate of the lipid as well as
by hydrogen bonding between the amino groups of the drug and
the carbonyl esters linked to glycerol [17]. Furthermore, bind-
ing of drug to anionic P1 altered the biophysical properties of
the liposome; for example, it depressed the permeability to
glycerol and stimulated membrane aggregation [17, 18]. Of
particular interest is that the rank order of AGs, with respect to
their ability to depress glycerol permeability and stimulate
aggregation of P1-containing liposomes (neomycin > gentami-
cm > tdbramycin > netilmicin), coincides precisely with their
established clinical nephrotoxicity potentials [18]. The toxico-
logical significance of AG binding to membrane phospholipid is
supported by other experiments involving polyaspartic acid
(PAA), a polymer of the anionic aspartic acid, which protects
rats against experimental AG nephrotoxicity without inhibiting
the renal accumulation of drug [19]. We have shown recently
that PAA completely inhibits gentamicin-induced perturbations
of phospholipid metabolism in cultured renal tubular cells and
prevents gentamicin from altering the biophysical properties of
P1-containing liposomes [20]. The mechanism of protection
involves inactivation of the AG by electrostatic complexation
with PAA.
Fig. 1. Major pathways by which drugs or
drug metabolites interact with cells to cause
toxic injury. Drug X or a stable metabolite
(Mx) may interact directly with sensitive
intracellular targets after attaining threshold
concentrations (pathways I and 4). X and Mx
may be enzymatically converted to a toxic
metabolite (Mx) which if it forms at a rate that
exceeds the detoxication pathway (5) reacts
with sensitive targets to cause injury.
(Adapted with permission from figure 1 in
HOOK JB; SMITH JA: Biochemical
mechanisms of nephrotoxicity. Transplant
Proc 17 (Suppl 1l):41—50, 1985).
Thus AGs provide an example of toxicity due to the intra-
cellular transport and accumulation of a drug that requires no
metabolic transformation for expression of toxicity (Fig. 1,
pathway 1). Although these drugs bind to and disrupt the
function and metabolism of multiple intracellular membranes
and organelles including plasma membranes, lysosomes, mi-
crosomes and mitochondria [5], the primary membrane target of
AGs has not been unequivocally established. The leading
hypothesis states that toxicity begins at the level of the lyso-
some where drug and phospholipid accumulate until a critical
concentration is reached that causes labilization of the lysosom-
al membrane [21]. Presumably the resulting redistribution of
drug and possibly potent lysosomal hydrolases to other cell
membranes and organelles propagates the injury cascade. In-
creased oxidative stress accompanies AG nephrotoxicity, but it
is a consequence rather than a causal mechanism of toxicity [22,
23].
Beta-lactam antibiotics
The beta-lactam antibiotics include the penicillins, the ceph-
alosponns and the thienamycins. Most of these drugs, being
organic anions, are actively transported by a carrier mediated
process across the basolateral membrane of renal proximal
tubular cells where they may attain high intracellular concen-
trations, and several have the potential to cause selective injury
and necrosis of these transporting cells [24]. The importance of
the organic anion transport system to the nephrotoxicity of
beta-lactam antibiotics is supported by the following: 1) toxicity
can be prevented by inhibitors of organic anion transport; 2)
toxicity is restricted to those cells of the proximal tubule where
the organic anion transport system resides; and 3) toxicity is not
observed with beta-lactams which are not secreted by the
organic anion transport system [24].
Cephaloridine was the first cephalosporin to be recognized as
nephrotoxic in humans. Detailed studies of the renal transport
of this drug in experimental animals have established that it is
readily taken up across the basolateral membrane by the
organic anion transport system; however, its rate of egress
across the lumenal membrane is significantly slower than that of
other secreted cephalosporins due to the fact that being a
zwitter ion, the cationic moiety impedes its passage across the
membrane [24]. Consequently at equivalent doses cephalori-
dine reaches proximal tubular cell concentrations substantially
higher than do other secreted cephalosporins. While high
intracellular concentration is a requirement for the expression
of toxicity, it may not be the most important determinant.
Comparative studies have established that cephaloglycin is
slightly more nephrotoxic than cephaloridine, yet peak and
sustained renal cortical concentrations of cephaloglycin are
significantly lower than those observed with equivalent doses of
cephaloridine and only slightly higher than those obtained with
non-nephrotoxic cephalosporins [24]. Clearly cephaloglycin
must have a greater potential than cephaloridine for interacting
at the molecular level with its intracellular target(s).
Two theories have been proposed to explair the molecular
toxicity of these agents: I) lipid peroxidation of cell membranes
and 2) mitocondrial injury. Cephaloridine has been shown to
induce lipid peroxidation accompanied by depletion of reduced
glutathione (GSH) and increased levels of oxidized glutathione
(GSSG) in the kidney of the rat and rabbit, and the nephrotox-
icity is potentiated by selenium deficiency and vitamin E
deficiency which augment lipid peroxidation [25]. The pyridin-
ium side chain of cephaloridine has been postulated to generate
superoxide anion via a redox reaction involving NADPH and
catalyzed by cytochrome P-450 reductase. The observation that
cephaloridine-induced stimulation of MDA formation is con-
centration and time dependent and precedes the nephrotoxic
related depression of transport function in renal cortical slices
suggests that lipid peroxidation is causally linked to the patho-
genesis of toxicity. However, this mechanism does not explain
the toxicity of cephaloglycin as a nephrotoxic dose of this agent
failed to induce in vivo the changes of lipid peroxidation and
oxidative stress observed with cephaloridine [26].
A growing body of evidence implicates mitochondnal respi-
ratory depression in the pathogenesis of cephalosporin nephro-
toxicity. Nephrotoxic cephalosporins inhibit mitochondrial res-
piration in vivo, the extent of which is proportional to their
nephrotoxicity potential [26—281. The onset of mitochondrial
respiratory depression can be detected 0.5 to 1 hour after
administration of a toxic dose of drug, it is irreversible, and it
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precedes by 5 to 10 hours the appearance of ultrastructural
mitochondrial damage which resembles that seen with ischemic
injury [26—28]. Many cephalosporins, both non-toxic as well as
toxic, have the potential to inhibit succinate-dependent mito-
chondrial respiration in vitro [29] by blocking succinate uptake
into the inner mitochondrial matrix [30]. In contrast to the
delayed onset after in vivo exposure, inhibition of mitochon-
dna! respiration after in vitro exposure to drug occurs within
five minutes and can be completely reversed during the early
phase by increasing the concentration of substrate. Tune [24]
proposed a model, derived from a synthesis of these observa-
tions, to explain the mitochondrial toxicity of cephalosporins.
The initial reversible depression of succinate-dependent mito-
chondrial respiration after in vitro exposure to cephalosporins
is mediated by competitive inhibition of the mitochondnial
carrier of anionic substrate. Irreversible depression is postu-
lated to be due to acylation of these carriers by reactive
cephalosporins. Beta-lactam antibiotics are known to form
covalent complexes with bacterial penicillin-binding proteins
(PBPs), and analysis of molecular structure indicates that
reactivity is determined by the stability of the bond linking the
R substituent to the 3-carbon position of the cephalosponin ring
[24]. In vitro studies have established the rank order of various
beta-lactam antibiotics with respect to their relative potencies
to acylate PBPs: cefaclor > cephaloglycin  cephaloridine >
cephalothin  cefazolin > several penicillins > cephalexin.
This order is at variance with the nephrotoxicity potentials of
beta-lactam antibiotics established from in vivo studies: ceph-
aloglycin > cephaloridine >> cefaclor> cefazolin >cephalo-
thin >> penicillin and cephalexin. The differences between the
rank order for reactivity and that for nephrotoxicity potential
can be explained by differences in the concentrative uptake of
these agents by renal proximal tubular cells. Although cefaclor
is a highly reactive acylator, the product of renal cortical drug
concentration and time, defined as the area under the curve
(AUC), is only 7% of that of cephaloridine and 37% of that of
cephaloglycin [24]. The nephrotoxicity potentials of beta-lac-
tam antibiotics, therefore, is determined both by their relative
reactivity as acylators of target proteins and by the amount of
drug (AUC) available to react with target proteins. This model
accurately predicts the rank order of the nephrotoxic cephalo-
sporins, Recent studies indicate that a similar mechanism of
mitochondrjal injury is a major factor in the pathogenesis of
imipenem nephrotoxicity [31]. Thus, the toxicity of these
agents, similar to AGs, is mediated by pathway 1 in Figure 1.
However, the mechanism of concentrative uptake, the primary
intracellular target and the mechanism of drug-target interaction
obviously differ from those associated with AG toxicity.
Biotransformation of drugs to toxic metabolites
Role of microsomal cytochrome P450-dependent mixed
function oxidases (MFO)
Cytochrome P-450-dependent MFO comprise a family of
microsomal enzymes of different substrate specificity that cat-
alyze a variety of oxidative reactions such as aromatic and
aliphatic hydroxylation, N-, 0- and S-dealkylations, sulfoxida-
tion, N-oxidation and epoxidation [1—3, 32, 33]. In addition to
cytochrome P-450, the oxidative system includes a reductase,
usually NADPH-cytochrome P-450 reductase (identical to
NADPH-cytochrome c reductase) but occasionally NADH-
cytochrome b5 reductase, and phosphatidyicholine. In the
kidney the cytochrome P-450 MFO system is found primarily in
the renal cortex; significantly less activity is located in the outer
medulla and no activity is detected in the inner medulla [34-361.
Within the renal cortex cytochrome P-450 MFO activity is
confined to cells of the proximal tubule, principally S2 and S3
segments (Table 1). NADPHcytochrome c reductase is also
distributed asymmetrically within the kidney and the highest
concentration is found in proximal tubular cells (Table 1) [36].
Endogenous substrates for the microsomal cytochrome P-450
system include fatty acids, steroids, fat soluble vitamins and
eicosanoids. This enzyme system also catalyzes the oxidation
of a wide variety of drugs as well as other xenobiotics and may
generate highly reactive and toxic metabolites [1—3, 32, 33]. The
metabolism of acetaminophen will be discussed to illustrate
bioactivation by the cytochrome P-450 system.
Acetaminophen, acetyl-p-aminophenol or APAP, is an effec-
tive and safe antipyretic and analgesic drug when used in
therapeutically recommended doses. In the clinical setting of
drug overdose APAP can cause hepatic injury often accompa-
nied by acute renal failure [37—39]. The risk of hepatic necrosis
and renal failure increases as a function of the magnitude of the
ingested dose of drug. In therapeutic doses APAP is readily
metabolized in the liver to glucuronyl and sulfate conjugates
which subsequently are eliminated in the urine; however, a
small fraction of APAP is metabolized by cytochrome P-450
MFO to a reactive intermediate that is inactivated by GSH and
is excreted as a conjugate of cysteine or mercapturic acid
[40—42]. Usually less than 2% of APAP is excreted unchanged in
the urine [40, 41]. When an overdose (typically greater than 15
grams) is ingested, the capacity of the liver to metabolize APAP
to glucuronyl and sulfate conjugates is exceeded and a larger
fraction is metabolized via the cytochrome P-450 system to a
reactive metabolite which is detoxified by reacting with GSH
(Fig. 2) This is reflected by the increased urinary excretion of
cysteine and mercapturic acid conjugates [41]. However, as
GSH levels become depleted, the reactive metabolite binds
covalently to macromolecules (Fig. 2) [43] and it is the arylation
of critical intracellular proteins that appears to be causally
linked to the induction of cellular injury [44].
Another consequence of ingesting an overdose of APAP is
that a larger quantity of unmetabolized drug is delivered to the
kidney as can be inferred from the elevated plasma concentra-
tion of APAP and from the increased excretion of unchanged
drug [41, 42]. The renal handling of APAP involves glomerular
filtration—only 13% is bound to plasma protein—followed by
passive tubular absorption which, depending on the diuretic
state, ranges from 60% to 74% of the filtered load in the dog
[45]. The kidney can metabolize APAP to glucuronyl and
sulfate conjugates but its capacity to do so is substantially less
than that of the liver [46]. Similar to the liver the kidney can also
metabolize APAP to an arylating intermediate via the cy-
tochrome P-450 system [47, 48]. The intrarenal distribution of
this enzyme system (Table 1) explains the finding that tubular
cell necrosis from acute APAP toxicity is restricted to the
proximal tubule [39, 471.
The conclusion that metabolism of APAP to a toxic metabo-
lite by cytochrome P-450-dependent MFO mediates acute tox-
icity is based primarily on animal studies of hepatotoxicity in
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Fig. 2. Pathways for the metabolism of
phenacerin and its major metabolites,
acetaminophen (APAP) and phenetidine, to
toxic intermediates. The dominant pathway is
indicated by the size of the arrows. PAP,
para-aminophenol; NAPQI, N-acetyl-p-
benzoquinoneimine; P-450, cytochrome P-450
mixed function oxidase; PGES, prostaglandin
endoperoxide synthetase. Consult text for
details.
which it was shown that: 1) induction of cytochrome P-450
augments toxicity and is accompanied by a dose-dependent
increase in covalent binding of radiolabeled APAP to macro-
molecules [43, 44, 49]; 2) inhibition of cytochrome P-450-
dependent MFO decreases covalent binding of radiolabeled
APAP to protein and prevents cellular necrosis [43, 44, 49]; and
3) maneuvers which promote GSH depletion augment covalent
binding of APAP and toxicity whereas maneuvers which main-
tain GSH levels have the opposite effects [50—53]. That a similar
cytochrome p-450 dependent mechanism mediates the acute
renal toxicity of APAP was inferred from the following obser-
vations in the Fischer (F) 344 rat: 1) APAP causes dose-
dependent depletion of renal GSH accompanied by reciprocal
increases in covalent binding of ['4C]APAP to renal proteins; 2)
similar to the findings in liver the covalent binding of ['4C]A-
PAP to renal protein is enzyme dependent and requires
NADPH and 02; 3) pretreatment with cobalt chloride, an
inhibitor of cytochrome P-450-dependent MFO activity, pro-
tected rats against APAP induced acute tubular necrosis, pre-
vented depletion of GSH, and greatly reduced APAP binding to
renal proteins in vivo and in vitro [471.
Recent studies by Newton et al [54—58] support the view that
an additional metabolic pathway involving para-aminophenol
(PAP) formation participates in the bioactivation of APAP. PAP
is the deacetylated derivative of APAP (Fig. 2) and when
administered to experimental animals causes renal functional
and histopathologic lesions identical to those induced by APAP
[54]. Of interest, PAP is 5 to 10 times as potent a nephrotoxicant
as APAP whereas it is has little toxicity for the liver. PAP,
similar to APAP, depletes renal cortical GSH and arylates renal
cortical proteins [55, 59], but the metabolic pathway for gener-
ating the reactive intermediate appears to be independent of the
microsomal cytochrome P-450 MFO system [56, 60]. Impor-
tantly, in the F344 rat PAP has been identified as a urinary
metabolite of APAP and is derived at least in part from the
deacetylation of APAP in the kidney [54, 551. Newton, Pasino
and Hook [57] have presented evidence that the deacetylase
pathway plays no appreciable role in the metabolic activation of
NCOCH3
PGES
G!ucuronjde
Sulfate
NHCOCH3 NHCOCH3
I l I ji
* P-450OH OCH2CH3
HENACETIND
NH2
__-I
OCH2CH3
(PHENETIDI
Glucuronide
Sulfate
P-450/
NH2 HONCOCH3
OH OH
PAP ?
NHCOCH3 NCOCH3(ii 'SG GSH PROTEIN
OH 0
(PQI )
NHCOCH3
S-PROTEIN
OH
@ELL INJU)
536 Kaloyanides: Role of drugs in nephrotoxicity
APAP in the liver. The significance of the deacetylase pathway
in the renal toxicity of APAP in the F344 rat is supported by the
demonstration that inhibition of deacetylase activity partially
protected rats against APAP but not PAP-induced functional
and histopathological lesions [58]. No direct information exists
about whether the deacetylase pathway is operational in hu-
mans. However, it is noteworthy that PAP was not identified as
a urinary metabolite in humans [40].
N-acetyl-p-benzoquinoneimine (NAPQI) has been proposed
as the toxic arylating cytochrome P-450-derived metabolite of
APAP (Fig. 2) [61—631. In support of this view NAPQI has been
shown to cause dose-dependent cytotoxicity in isolated hepa-
tocytes [641. Initially NAPQI is detoxified by conjugation with
GSH, but as GSH is depleted it interacts with cellular macro-
molecules causing oxidation or arylation of proteins, principally
at thiol groups [64, 65]. At this time it remains uncertain
whether protein arylation or oxidative stress is the more impor-
tant determinant of NAPQI cytotoxicity as support can be
found for both possibilities [66, 67]. Disruption of intracellular
calcium homeostasis may be linked to the injury cascade
triggered by NAPQI [66]. Benzoquinoneimine has been pro-
posed as the reactive intermediate generated from PAP [59], but
no evidence in support of this hypothesis has been presented.
The Sprague-Dawley (SD) rat, in contrast to the F344 rat, is
resistant to APAP-induced nephrotoxic injury [49, 551 and is
less sensitive than the F344 rat to PAP nephrotoxicity [54].
Compared to the F344 rat the SD rat has lower renal cortical
cytochrome P-450 and deacetylase activities [681 and lower
rates of covalent binding of reactive metabolite to renal mi-
crosomal protein [55]. The homozygous Gunn rat suffers from a
genetic deficiency of UDP-glucuronyl transferase and conse-
quently exhibits increased susceptibility to APAP hepato- and
nephrotoxicity [69]. These observations serve to emphasize
that genetic factors are an important determinant of the meta-
bolic pathways and the metabolic rates at which xenobiotics
undergo bioactivation and/or detoxification and, hence, may
influence the susceptibility of the kidney to injury from poten-
tial nephrotoxicants.
In summary, acute APAP nephrotoxicity represents an ex-
ample of injury due to metabolic activation of a drug (Fig. 1,
pathway 3) at a rate that exceeds the capacity of the detoxifying
mechanisms (Fig. 1, pathway 5).
Role ofprostaglandin endoperoxide synthetase
The first step in the synthesis of prostaglandins from arachi-
donic acid is catalyzed by prostaglandin endoperoxide syn-
thetase (PGES), which is also known as prostaglandin H
synthase [70]. PGES is comprised of two enzymatic activities,
a cyclooxygenase and a hydroperoxidase [71]. The cyclooxy-
genase catalyzes the conversion of arachidonic acid to PGG2, a
15-hydroperoxy PG cyclic endoperoxide. The hydroperoxidase
catalyzes the reduction of PGG2 to PGH2, a process that
requires reducing equivalents. Previous studies using PGES
from seminal vesicles have demonstrated that xenobiotics can
serve as electron donors for the hydroperoxidase reaction and
in the process undergo co-oxidation to either a stable or
occasionally to a reactive metabolite (Fig. 3) [72, 73]. A similar
mechanism of co-oxidation of xenobiotics has been shown to
occur in the inner medulla, the renal site highest in PGES
Arachidonic acid Unsaturated fatty acids
Lipoxygenases
Cyclo-oxygena,/" '\\iPd Peroxio,77
PGH2 Lipid hydroperoxide
(ROOH)
XH
Prostaglandin hydroperoxidase Hydroperoxidase
Stable Stable
and reactive — X. .—/ \ / X• - and reactive
metabolites
pGG2—" "NROH___" metabolites
Fig. 3. Peroxidase-catalyzed co-oxidation of xenobiotics. The catalytic
reduction of PGG2 or other lipid hydroperoxides requires an electron
donor which usually is an endogenous substrate. However, certain
xenobiotics may substitute as electron donors for this reductive reac-
tion and in the process are oxidized to toxic intermediates. (Reproduced
with permission from MOLDEUS P, Ross D, LARSSON R: Interrelation-
ships between xenobiotic metabolism in lipid biochemistry. Biochem
Soc Trans 13:847—850, 1985.)
activity (Table 1). Moreover, this mechanism of co-oxidation
can generate carcinogens and nephrotoxicants [73, 74].
Phenacetin has been implicated in the pathogenesis of renal
papillary necrosis associated with chronic analgesic abuse [75].
The major metabolite of phenacetin is APAP which is formed in
the liver via the cytochrome P-450 system (Fig. 2) [76]. Of
interest, phenacetin overdosage does not cause hepatic or renal
failure because the rate of APAP generation does not exceed
the rate at which APAP can be conjugated with glucuronide,
sulfate or GSH [76]. Chronic abuse of phenacetin containing
analgesics, however, results in the long-term exposure of the
papilla to low concentrations of APAP. Several investigators
have demonstrated that APAP can undergo co-oxidation by the
hydroperoxidase activity of prostaglandin endoperoxide syn-
thetase [35, 72, 77—79] to form the reactive intermediate,
NAPQI [65—67]. Whereas the inner medulla has the highest
PGES activity of the kidney [34, 35, 70], the cells of this region
have low concentrations of GSH and a limited capacity to
regenerate or synthesize GSH [80]. This unique distribution of
enzymes involved in the bioactivation and detoxification of
reactive metabolites, together with the fact that APAP is
concentrated in this region of the kidney [75], has been ad-
vanced as the explanation for the vulnerability of the inner
medulla to injury from long-term exposure to low dose APAP or
phenacetin [80].
Aspil:in (acetylsalicylic acid), a common component with
phenacetin in compound analgesics, has also been implicated in
the pathogenesis of papillary necrosis [751. Aspirin in sufficient
concentration can inhibit the cyclo-oxygenase component of
PGES; but it has no effect on the hydroperoxidase component
[79]. Aspirin undergoes deacetylation to salicylic acid which
during antidiuresis accumulates in high concentration within
cells of the inner medulla [75]. Salicylic acid has no inhibitory
effect on either component of PGES [79]; however, it has been
shown to deplete the kidney of GSH [75], an effect which would
magnify the nephrotoxic potential of APAP.
Recent studies raise the possibility that p-phenetidine, the
deacetylated derivative of phenacetin (Fig. 2), may also play a
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role in the pathogenesis of papillary necrosis associated with
chronic phenacetin abuse. Like APAP, p-phenetidine has been
shown to be an excellent substrate for co-oxidation by PGES
from the renal medulla, the products of which are N-(4-
ethoxyphenyl)p-benzoquinoneimine (NEPBQI) and N-(4-
ethoxyphenyl)p-benzoquinonedi-imine (Fig. 2) [81]. NEPBQI
binds GSH, arylates microsomal proteins [81, 82] and is cyto-
toxic [831. In addition, an unidentified primary oxidation prod-
uct of p-phenetidine is genotoxic [82]. Genetic or drug-induced
variation in the rate of p-phenetidine formation in the liver or
possibly within cells of the renal medulla may be an important
determinant of phenacetin nephrotoxicity.
In summary, the nephrotoxicity associated with phenacetin
abuse represents an example of injury mediated by the meta-
bolic activation in the renal inner medulla of a stable metabolite
formed in the liver (Fig. I, pathway 4).
Role of y glutamyltranspeptidase and the formation of
cysteine S-conjugates
Glutathione (GSH) is a ubiquitous tripeptide (L-y-glutamyl-
L-cysteinylglycine) that participates in many biological processes
including the synthesis of proteins and DNA, transport of amino
acids, modulation of enzyme activity, metabolism of endogenous
and exogenous substrates and the detoxication of reactive metab-
olites [84]. The first step in the metabolism of xenobiotics and their
metabolites involves the formation of GSH S-conjugates. This
reaction can occur spontaneously in the case of highly electro-
philic compounds or it can be catalyzed by GSH S-transferases. a
family of enzymes with broad and overlapping substrate specific-
ities [85]. GSH S-transferases are present in many cells; however,
impressively high levels are found in the liver. Sequential steps in
the metabolism of GSH S-conjugates include splitting of the
.-glutamyl bond by y.glutamyltranspeptidase ()GT) to form
S-cysteinylglycine conjugates, followed by dipeptidase degrada-
tion to cysteine S-conjugates which can be N-acetylated to mer-
capturic acids or further metabolized by 13-lyase to thiol deriva-
tives (Fig. 4) [84—86]. As a general rule the formation of GSH
S-conjugates represents a detoxication pathway for many reactive
xenobiotics and metabolites. However, for certain substrates,
mainly halogenated hydrocarbons, formation of GSH S-conju-
gates represents a bioactivation pathway that generates nephro-
toxic, hepatotoxic, mutagenic and/or carcinogenic metabolites
[85—88]. The susceptibility of the kidney to toxic injury by this
pathway relates to the major role the kidney plays in the formation
and processing of toxic cysteine S-conjugates. Several reviews of
this subject have appeared recently [86—88].
Halogenated alkanes and alkenes are substrates for liver
GSH S-transferases which catalyze the formation of GSH
S-conjugates. For example, the reaction of trichioroethylene
with GSH generates S-(1,2 dichlorovinyl)glutathione (DCVG),
the precursor of a nephrotoxic derivative [89]. The formation in
the liver of S-(pentachloro-l,3-butadienyl) glutathione (PCBG)
from the GSH S-transferase catalyzed reaction of GSH with
hexachloro-l,3-butadiene represents another example [90].
GSH S-conjugates are transported from hepatocytes into
plasma and bile, following which they are degraded sequentially
by )GT and dipeptidases to form the corresponding cysteine
S-conjugates. yGT is present on the surface membranes of
many cells including biliary tract epithelium, jejunal epithelium
and renal proximal tubular epithelium, both lumenal and baso-
lateral membranes 184, 86]. Of toxicological significance the
kidney exhibits the highest >43T activity of any organ or tissue
[84, 86]. GSH S-conjugates transported into plasma are deliv-
ered to the kidney, where after glomerular filtration they are
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Fig. 4. Pathways for the metabolism of glutathione conjugates. Some cysteine conjugates are directly toxic following uptake by renal proximal
tubules or are metabolized by cysteine conjugate /3-lyase to toxic thiol metabolites. (Reproduced with permission from PIcKErr B, Lu AYH:
Glutathione S—transferases: Gene structure, regulation and biological function. Ann Rev Biochem 58:743—764, 1989.)
538 Kaloyanides: Role of drugs in nephrotoxicity
catabolized by yGT and cysteinyiglycine dipeptidase to form
the cysteine S-conjugates which are transported across the
apical membrane [85]. An unknown quantity of the GSH
S-conjugates may be degraded by GT on the basolateral
membrane or transported directly into the cell by a sodium-
dependent probenecid inhibitable pathway [91]. This pathway
appears to be distinct from that which mediates the active
uptake of cysteine S-conjugates [91, 92]. Conflicting data exists
concerning the role of organic anion transport in mediating the
active uptake of these conjugates [92, 93]. The fate of GSH
S-conjugates which are transported from hepatocytes into bile
has not been studied in detail, but it seems that an unknown
quantity is returned to the circulation and processed by renal
proximal tubular cells [86].
Nephrotoxic cysteine S-conjugates can cause proximal tubu-
lar cell injury by two major pathways. Certain nephrotoxic
conjugates, such as S-(2-chloroethyl)cysteine, undergo sponta-
neous rearrangement to form an episulfonium ion which can
cause toxic injury by interacting with nucleophilic groups of
critical macromolecules [87, 88]. In other cases the cysteine
S-conjugate is the penultimate nephrotoxin that becomes acti-
vated by renal /3-lyase [87, 88]. S-(1,2 dichlorovinyl)cysteine
exemplifies this mechanism [89]. Mitochondria appear to be a
major target of the toxic metabolites generated by renal J3-lyase
[94]. In vitro studies have demonstrated that incubation of
isolated renal cortical mitochondria with known toxic cysteine
S-conjugates results in disruption of the function, metabolism
and structural integrity of these organelles. The susceptibility of
mitochondria to injury from cysteine S-conjugates can be
explained by the observation that most of the /3-lyase activity in
renal tubular cells is found in the mitochondrial fraction [89].
Thus, the nephrotoxicity associated with cysteine S-conjugates
of halogenated hydrocarbons represent examples of injury
mediated by pathway 2 and pathway 4 in Figure 1.
Conclusion
In this brief review the generic pathways by which drugs
interact with cells of the tubulo-interstitium to cause toxicity
have been emphasized. Although the potential number of
toxicants is large and rapidly expanding, the basic pathways by
which they exert their toxic effect are few in number. The
selective vulnerability of specific cells of the kidney, for exam-
ple, proximal tubular cells, to certain drugs and xenobiotics is a
predictable consequence of the unique transport and/or meta-
bolic profile of such cells that results in the generation and/or
accumulation of the offending toxicant. At the present time
huge gaps exist in our knowledge of the ultimate toxic species of
many agents, the specific targets of the toxicant and how the
interaction of the toxicant with its target eventuates in cellular
injury or death. As our understanding of specific molecular
mechanisms mediating toxicity expands, it should be possible
to devise strategies for protecting the kidney from a major cause
of injury.
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